Levofloxacin induced exfoliative dermatitis in a tuberculosis retreatment patient: A case report
Levofloxacin induced exfoliative dermatitis
DOI:
https://doi.org/10.3329/bmrcb.v47i3.59247Keywords:
Levofloxacin, Exfoliative dermatitis, Cat-2 Anti-TB drugs, RetreatmentAbstract
Background: Levofloxacin shows high bactericidal activity against mycobacterium tuberculosis with excellent safety profile. Rare adverse reactions include autoimmune haemolytic anaemia, hypoglycaemia, visual hallucinations, fixed drug eruptions, etc. Till date, only two cases of exfoliation associated with the Levofloxacin have been reported so far.
Objective: To review exfoliative dermatitis associated with the Levofloxacin and its prognosis in a retreatment case of mycobacterium tuberculosis.
The case: A 65 years old male was diagnosed as a case of Pulmonary TB, based on GeneXpert of Sputum examination. He was started on 1st line Anti-Tb drugs. No adverse drug reaction was reported at that time. Though he completed full 6 months course of anti-TB drugs, he was again tested positive for mycobacterium tuberculosis 2 months back and was started on Cat-2 Anti-TB drugs after being categorised as “RETREATMENT”. Just 20 days back before his admission to this hospital in May 2021, he developed cough. He also developed fever 7 days back and generalised itching with exfoliation of skin for 6 days. This cutaneous reaction occurred after starting Levofloxacin.
Conclusion: Immediately after detection, the responsible drug should be withheld, and treatment should be in a multi-disciplinary approach. Further studies are suggested for determination of potentials of cutaneous and other adverse reaction with the use of Levofloxacin along with 4-FDC in Rifampicin-sensitive retreatment category patients.
Bangladesh Med Res Counc Bull 2021; 47(3): 327-330
Downloads
25
30
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 Md Ali Akbar Khan, Md Titu Miah, Shah Mubdi-Un-Naafi
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms.
Authors retain copyright and grant the journal right of first publication.
Articles in the Bangladesh Medical Research Council Bulletin are licensed under a Creative Commons Attribution 4.0 International License (CC-BY) that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).